Literature DB >> 9333267

Chromosome 19 single-locus and multilocus haplotype associations with multiple sclerosis. Evidence of a new susceptibility locus in Caucasian and Chinese patients.

L F Barcellos1, G Thomson, M Carrington, J Schafer, A B Begovich, P Lin, X H Xu, B Q Min, D Marti, W Klitz.   

Abstract

CONTEXT: Susceptibility to multiple sclerosis (MS) involves a genetically complex autoimmune component. However, except for genes in the HLA system, specific susceptibility loci are unknown or unconfirmed.
OBJECTIVE: To investigate several loci spanning 3 candidate regions for a role in multiple sclerosis (MS) susceptibility in 2 ethnic groups using both single-locus and haplotype analyses. The 3 regions include HLA on chromosome 6p21.3, APOE on chromosome 19ql 3.2, and MBP(myelin basic protein) on chromosome 18q23.
DESIGN: Case-control association testing.
SUBJECTS: A total of 120 Caucasian patients with MS and 107 unrelated control individuals from California, and 32 patients and 32 unrelated control individuals from Beijing, China. All patients with MS were diagnosed as having clinically definite disease according to published criteria. MAIN OUTCOME MEASURES: Chi2 Testing of loci and individual alleles and haplotypes. Haplotype frequencies were estimated with standard maximum likelihood methods.
RESULTS: The HLA effect is due to the class II DR2 haplotype, DRB1*1501-DQA1*0102-DRB1*0602; contributions to MS susceptibility from additional DRB1-DQB1 alleles or other HLA region loci were not observed. Variation within the MBP locus on chromosome 18q23 showed no effect in MS. The distribution of haplotypes from 5 loci within the chromosome 19q13.2 region, including D19S178, D19S574, APOE, APOC2, and D19S219, differed between patient and control samples. D19S574 showed a significant effect (P=.015) in Caucasian patients with MS due to the increased frequency of a single allele (P=.002). The APOE variation, prominent in other neurological diseases, showed no influence on MS susceptibility, despite its location within the chromosome 19q13.2 region. Interaction effects between DR2 and chromosome 19q13.2 or MBP in MS susceptibility were not apparent.
CONCLUSIONS: The significant chromosome 19q13.2 single-locus and multilocus haplotype associations with MS in Caucasian and Chinese patient samples indicate an effect from a nearby disease susceptibility locus. These initial observations are an encouraging step toward the description of non-HLA genetic susceptibility to MS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333267

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  10 in total

Review 1.  The genetic epidemiology of multiple sclerosis.

Authors:  A Compston
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

2.  Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis.

Authors:  R J Butterfield; E P Blankenhorn; R J Roper; J F Zachary; R W Doerge; C Teuscher
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 3.  Targeting oligodendrocyte protection and remyelination in multiple sclerosis.

Authors:  Jingya Zhang; Elisabeth G Kramer; Sean Mahase; Dipankar J Dutta; Virginie Bonnamain; Azeb T Argaw; Gareth R John
Journal:  Mt Sinai J Med       Date:  2011 Mar-Apr

4.  Analysis of allelic association between D6S461 marker and multiple sclerosis in Ashkenazi and Iraqi Jewish patients.

Authors:  Y Shinar; E Pras; I Siev-Ner; D Gamus; C Brautbar; S Israel; A Achiron
Journal:  J Mol Neurosci       Date:  1998-12       Impact factor: 3.444

5.  Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis.

Authors:  Silke Schmidt; Lisa F Barcellos; Karen DeSombre; Jacqueline B Rimmler; Robin R Lincoln; Patricia Bucher; Ann M Saunders; Eric Lai; Eden R Martin; Jeffery M Vance; Jorge R Oksenberg; Stephen L Hauser; Margaret A Pericak-Vance; Jonathan L Haines
Journal:  Am J Hum Genet       Date:  2002-02-11       Impact factor: 11.025

6.  A follow-up study of chromosome 19q13 in multiple sclerosis susceptibility.

Authors:  Alessandro Bonetti; Keijo Koivisto; Tuula Pirttilä; Irina Elovaara; Mauri Reunanen; Mikko Laaksonen; Juhani Ruutiainen; Leena Peltonen; Terhi Rantamäki; Pentti J Tienari
Journal:  J Neuroimmunol       Date:  2009-02-04       Impact factor: 3.478

7.  Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission.

Authors:  Ariel T Arthur; Patricia J Armati; Chris Bye; Robert N S Heard; Graeme J Stewart; John D Pollard; David R Booth
Journal:  BMC Med Genet       Date:  2008-03-19       Impact factor: 2.103

8.  Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort.

Authors:  Helga Westerlind; Kerstin Imrell; Ryan Ramanujam; Kjell-Morten Myhr; Elisabeth Gulowsen Celius; Hanne F Harbo; Annette Bang Oturai; Anders Hamsten; Lars Alfredsson; Tomas Olsson; Ingrid Kockum; Timo Koski; Jan Hillert
Journal:  Eur J Hum Genet       Date:  2014-08-27       Impact factor: 4.246

9.  Serum Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3) Is Increased in Patients with Multiple Sclerosis and Is a Strong Independent Indicator of Disease Severity; 6.7kbp LILRA3 Gene Deletion Is Not Associated with Diseases Susceptibility.

Authors:  Hongyan An; Chai Lim; Gilles J Guillemin; Ute Vollmer-Conna; William Rawlinson; Katherine Bryant; Nicodemus Tedla
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

10.  Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes.

Authors:  Nellie A Martin; Arkadiusz Nawrocki; Viktor Molnar; Maria L Elkjaer; Eva K Thygesen; Miklos Palkovits; Peter Acs; Tobias Sejbaek; Helle H Nielsen; Zoltan Hegedus; Finn Sellebjerg; Tihamer Molnar; Eudes G V Barbosa; Nicolas Alcaraz; Ferenc Gallyas; Asa F Svenningsen; Jan Baumbach; Hans Lassmann; Martin R Larsen; Zsolt Illes
Journal:  PLoS One       Date:  2018-08-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.